CATEGORIES: CMT Summit | CMT Update

About The Summit Venue: 3 West Club, New York City

by | May 26, 2016 | 0 comments

Grand Salon - Lunch

Grand Salon – Lunch

The Hereditary Neuropathy Foundation has selected historic 3 West Club to hold the first Patient-Centered Charcot-Marie-Tooth Summit on October 6, 2016.

The 3 West Club is a best-in-class event space and boutique hotel nestled in the heart of Midtown Manhattan. Located in an historical building, you instantly get that classic “Old New York” feel when you walk through their doors.

3 West Club is just off 5th Avenue, only steps away from Rockefeller Center and Radio City Music Hall.

Unique styling, prime location, and that classic New York atmosphere make 3 West Club the perfect place to hold the first Patient-Centered Charcot-Marie-Tooth Summit!

For more information:
3 West Club
3 West 51st New York, NY 10019
(212) 582-5454
[email protected]

Learn more on this topic

Related Blog Posts

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

In Memoriam

The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news